Editorial Staff

Alzheimer Breakthrough Disillusionment: Confusion on FDA’s Approval of Expensive and Possibly Ineffective Drug

/in , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Hubwonk host Joe Selvaggi talks with precision medicine expert Hannah Mamuszka and Pioneer Institute’s Bill Smith about the promises and pitfalls of the newly approved Alzheimer’s drug Aduhelm, and the challenges presented when new, expensive drugs of dubious benefit are introduced to the nation’s formulary.

Guest:

Hannah Mamuszka is Founder & CEO of ALVA10, a healthcare technology firm. Hannah has spent her 20+ year career in diagnostics – both in pharma and at diagnostics companies, in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data. She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.

Guest Host:

Dr. William S. Smith is Pioneer’s Visiting Fellow in the Life Sciences. Dr. Smith has 25 years of experience in government and in corporate roles. His career includes senior staff positions for the Republican House leadership on Capitol Hill, the White House Office of National Drug Control Policy, and the Massachusetts Governor’s office where he served under Governors Weld and Cellucci. He spent ten years at Pfizer Inc as Vice President of Public Affairs and Policy where he was responsible for Pfizer’s corporate strategies for the U.S. policy environment. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies. Dr. Smith earned his PhD in political science with distinction at The Catholic University of America.

Get new episodes of Hubwonk in your inbox!

Recent episodes:

Tax Man Confounded: Why High Rates Haven’t Yielded Higher Revenue

Joe Selvaggi talks with economic scholar Dr. Brian Domitrovic about the history of federal tax policy and the reasons for why varied marginal rates fail to correlate with either tax revenue or GDP growth.

Industrial Policy Reimaged: Can Government Improve Free Markets

Joe Selvaggi discusses industrial policy, its aspirations and limitations, with CATO Institute Associate Director Colin Grabow, in response to Senator Rubio's thought piece advocating for a more active role for government in the economy.

Posting Patient Prices: Transparency Cure for Hospital Blank Checks

Joe Selvaggi interviews entrepreneur, philanthropist, and founder of PatientRightsAdvocate.org, Cynthia Fisher, discussing her research and advocacy for enhanced healthcare price transparency. This initiative has the potential to improve life expectancy and save Americans over a trillion dollars annually.

Constitutional Property Taking: Exclusionary Zoning’s Costs to Owners and Society

Joe Selvaggi talks with George Mason Law Professor Ilya Somin about the the costs, benefits, and legal foundations of exclusionary zoning argued in his recent paper: The Constitutional Case Against Exclusionary Zoning. 

Poor Housing Incentives: Tax Credits Reward Politicians Not Neighbors in Need

Joe Selvaggi interviews Chris Edwards, Chair of Fiscal Studies at CATO Institute, about his research on the 40-year history of Low-Income Housing Tax Credits. They delve into its features, effects, and potential alternatives that could provide greater benefits at lower costs to taxpayers.

Biden’s Budget Breakdown: Pragmatic Progress or Political Posturing

Joe Selvaggi talks with Manhattan Institute Senior Fellow Brian Reidl about how the contours of President Biden’s recently released budget proposal reveal a persistent, bipartisan reluctance to address profound structural deficits.

Genetic Therapy Revolution: Benefits and Barriers for Medicine’s New Horizon

Joe Selvaggi talks with neurobiologist and writer Dr. Anne Sydor about the potential for gene therapy to address deadly and debilitating diseases and how current health care models must adapt to encourage this nascent technology.

Contours of Content Curation: SCOTUS Hears Online Free Speech Cases

Cato Institute's Thomas Berry, talks about oral arguments at the Supreme Court in the NetChoice cases, exploring the First Amendment questions that affect both social media users and the platforms that curate their content.

Mortgage’s New Normal: Guide to Better Borrowing Amidst Higher Rates

Joe Selvaggi talks with mortgage expert, Trip Miller of Cambridge Savings Bank, about mortgage rates and trends and explores best practices for finding a mortgage structure that suits individual buyers’ needs.

Medicaid’s Massive Miasma: Taming Beacon Hill’s Burgeoning Budget Beast

Marc Joffe, a state policy analyst at the Cato Institute, talks about his research on Medicaid's cost and size. They explore how Massachusetts can control spending growth while protecting other priorities.